D
Dinesh Kumar Sinha
Researcher at Indira Gandhi Institute of Medical Sciences
Publications - 15
Citations - 244
Dinesh Kumar Sinha is an academic researcher from Indira Gandhi Institute of Medical Sciences. The author has contributed to research in topics: Bortezomib & Dexamethasone. The author has an hindex of 3, co-authored 13 publications receiving 92 citations.
Papers
More filters
Journal ArticleDOI
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label phase 3 trial
Sebastian Grosicki,Maryana Simonova,Ivan Spicka,Ludek Pour,Iryrna Kriachok,Maria Gavriatopoulou,Halyna Pylypenko,Holger W. Auner,Xavier Leleu,Vadim A Doronin,Ganna Usenko,Nizar J. Bahlis,Roman Hájek,Reuben Benjamin,Tuphan Kanti Dolai,Dinesh Kumar Sinha,Christopher P. Venner,Mamta Garg,Mercedes Gironella,Artur Jurczyszyn,Pawel Robak,Monica Galli,Craig T. Wallington-Beddoe,Atanas Radinoff,Galina Salogub,Don A. Stevens,Supratik Basu,Anna M. Liberati,Hang Quach,Vesselina Goranova-Marinova,Jelena Bila,Eirini Katodritou,Hanna Oliynyk,Sybiryna Korenkova,Jeevan Kumar,Sundar Jagannath,P. Moreau,Moshe Yair Levy,Darrell White,Moshe E. Gatt,Thierry Facon,Maria V. Mateos,Michele Cavo,Donna E. Reece,Larry D. Anderson,Jean Richard Saint-Martin,Jacqueline Jeha,Anita A. Joshi,Yi Chai,Lingling Li,Vishnuvardhan Peddagali,Melina Arazy,Jatin P. Shah,Sharon Shacham,Michael G. Kauffman,Meletios A. Dimopoulos,Paul G. Richardson,Sosana Delimpasi +57 more
TL;DR: This phase 3, randomised, open-label trial aimed to evaluate the clinical benefit of weekly selinexor, bortezomib, and dexamethasone versus standard bortzomib and dex amethas one in patients with previously treated multiple myeloma.
Journal ArticleDOI
Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.
Meletios A. Dimopoulos,Sosana Delimpasi,Maryana Simonova,Ivan Spicka,Ludek Pour,Iryna Kryachok,Maria Gavriatopoulou,Halyna Pylypenko,Holger W. Auner,Xavier Leleu,Vadim A Doronin,Polina Kaplan,Roman Hájek,Benjamin Reuben,Tuphan Kanti Dolai,Dinesh Kumar Sinha,Melina Arazy,Paul G. Richardson,Nizar J. Bahlis,Sebastian Grosicki +19 more
TL;DR: Selinexor is an oral, selective inhibitor of XPO1-mediated nuclear export, leading to the reactivation of tumor suppressor proteins, and in a phase 1b/2 study, the combination of once-weekly injections of this drug with EMT reversed the activity of these proteins.
Journal ArticleDOI
Effect of Age and Frailty on the Efficacy and Tolerability of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma
Holger W. Auner,Maria Gavriatopoulou,Sosana Delimpasi,Maryana Simonova,Ivan Spicka,Ludek Pour,Meletios A. Dimopoulos,Iryna Kriachok,Halyna Pylypenko,Xavier Leleu,Vadim A Doronin,Ganna Usenko,Roman Hájek,Reuben Benjamin,Tuphan Kanti Dolai,Dinesh Kumar Sinha,Christopher P. Venner,Mamta Garg,Don A. Stevens,Hang Quach,Sundar Jagannath,P. Moreau,Moshe Yair Levy,Ashraf Z. Badros,Larry D. Anderson,Nizar J. Bahlis,Thierry Facon,Maria-Victoria Mateos,Michele Cavo,Yi Chai,Melina Arazy,Jatin P. Shah,Sharon Shacham,Michael Kauffman,Paul G. Richardson,Sebastian Grosicki +35 more
TL;DR: The phase 3 Boston trial as mentioned in this paper showed that once-weekly selinexor and bortezomib with low-dose dexamethasone (XVd) improved PFS and ORR compared with standard twice-weekly borteasomib and moderate-dose DDA in patients with previously treated multiple myeloma.
Journal ArticleDOI
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Shambavi Richard,Ajai Chari,Sosana Delimpasi,Maryana Simonova,Ivan Spicka,Ludek Pour,Iryna Kriachok,Meletios A. Dimopoulos,Halyna Pylypenko,Holger W. Auner,Xavier Leleu,Ganna Usenko,Roman Hájek,Reuben Benjamin,Tuphan Kanti Dolai,Dinesh Kumar Sinha,Christopher P. Venner,Mamta Garg,Don A. Stevens,Hang Quach,Sundar Jagannath,P. Moreau,Moshe Yair Levy,Ashraf Z. Badros,Larry D. Anderson,Nizar J. Bahlis,Thierry Facon,Maria-Victoria Mateos,Michele Cavo,Hua Chang,Yosef Landesman,Yi Chai,Melina Arazy,Jatin P. Shah,Sharon Shacham,Michael Kauffman,Sebastian Grosicki,Paul G. Richardson +37 more
TL;DR: In the phase 3 Boston study, patients with multiple myeloma (MM) after 1-3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly borthemib-drug examethase (Vd), and XVd was associated with significant improvements in median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy,
Journal ArticleDOI
Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer
TL;DR: In this paper , the authors compared tumor marker levels between GBC and benign GB diseases (GBDs) and assessed the combined use of tumor markers to increase the diagnostic accuracy for GBC.